Clinical surrogate end-points
نویسندگان
چکیده
منابع مشابه
Surrogate end points in clinical trials: are we being misled?
Phase 3 clinical trials, which evaluate the effect that new interventions have on the clinical outcomes of particular relevance to the patient (such as death, loss of vision, or other major symptomatic event), often require many participants to be followed for a long time.There has recently been great interest in using surrogate end points, such as tumor shrinkage or changes in cholesterol leve...
متن کاملSurrogate end points for clinical trials of kidney disease progression.
C hronic kidney disease (CKD) worsens over time by transitions through a sequence of stages, regardless of the specific cause of kidney damage or rate of progression (Figure 1). Recent guidelines and public health campaigns have focused on early detection and treatment of CKD on the basis of the rationale that treatments that are initiated early in the disease course will have a greater effect ...
متن کاملSurrogate end points in clinical research: hazardous to your health.
Surrogate end points in clinical research pose real danger. A surrogate end point is an outcome measure, commonly a laboratory test, that substitutes for a clinical event of true importance. Resistance to activated protein C, for example, has been used as a surrogate for venous thrombosis in women using oral contraceptives. Other examples of inappropriate surrogate end points in contraception i...
متن کاملSurrogate end points: hopes and perils.
In recent years, the cost of drug development has increased the demands on efficiency in the selection of suitable drug candidates; surrogate end points have emerged to improve this process, hoping that they can help reduce duration and cost of clinical trials. Additionally, they can help in solving ethical issues when measuring the clinical end point involves the application of risky or uncomf...
متن کاملUse of Surrogate end points in HTA
The different actors involved in health system decision-making and regulation have to deal with the question which are valid parameters to assess the health value of health technologies.So called surrogate endpoints represent in the best case preliminary steps in the casual chain leading to the relevant outcome (e. g. mortality, morbidity) and are not usually directly perceptible by patients. S...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Cancer Supplements
سال: 2007
ISSN: 1359-6349
DOI: 10.1016/j.ejcsup.2007.09.026